First report of post-transplant autoimmune hepatitis recurrence following SARS-CoV-2 mRNA vaccination
Transplant Immunology, ISSN: 0966-3274, Vol: 72, Page: 101600
2022
- 9Citations
- 36Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef4
- Captures36
- Readers36
- 36
Article Description
Whilst vaccination for the SARS-CoV-2 virus has been successful in reducing the severity and burden of the COVID-19 pandemic, there have been recent reports of mRNA vaccines triggering autoimmune hepatitis in the native liver. There have been no descriptions thus far of recurrent ‘autoimmune hepatitis’ after liver transplantation in the context of SARS-CoV-2 vaccination. We describe a patient transplanted for autoimmune hepatitis who was stable for many years until they had immune-mediated flares coinciding with Pfizer-BioNTech mRNA vaccination. Intravenous steroid treatment was required to suppress histologically evident interface hepatitis. We firmly believe that mRNA vaccination was responsible for this ‘recurrence’ and that clinicians should be vigilant for this reaction in patients transplanted for autoimmune hepatitis.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0966327422000740; http://dx.doi.org/10.1016/j.trim.2022.101600; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85127467430&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/35390478; https://linkinghub.elsevier.com/retrieve/pii/S0966327422000740; https://dx.doi.org/10.1016/j.trim.2022.101600
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know